top of page
Search

Brazil Medical Cannabis Market Size, Share, Trends, Growth, Forecast, Outlook, Report 2026-2034

  • Writer: Lakshy Gagda
    Lakshy Gagda
  • Jan 2
  • 4 min read

Market Overview


The Brazil medical cannabis market size reached USD 856.53 Million in 2025 and is projected to grow to USD 1,546.74 Million by 2034, registering a CAGR of 6.79% during the forecast period of 2026-2034. Growth is driven by expanding therapeutic uses, advances in cultivation techniques, and digital integration improving patient access and treatment efficiency. Regulatory support and growing clinical acceptance further bolster market expansion, reflecting a maturing industry set for steady growth.


Study Assumption Years


  • Base Year: 2025

  • Historical Year/Period: 2020-2025

  • Forecast Year/Period: 2026-2034


Brazil Medical Cannabis Market Key Takeaways


  • The market size was USD 856.53 Million in 2025.

  • The market is forecasted to grow at a CAGR of 6.79% during 2026-2034.

  • The forecast period spans 2026-2034.

  • Medical cannabis is being increasingly accepted for treating chronic pain, neurological disorders, and palliative care.

  • New product varieties like oils, capsules, and transdermal delivery systems are improving patient compliance.

  • Regulatory adaptations and court decisions in 2024 are enhancing patient access to cannabis-based medicines.

  • Technological advances in cultivation are improving product quality, scalability, and sustainability.




Market Growth Factors


The medical cannabis market in Brazil has expanded of late to include drugs for chronic pain, neurological diseases, and palliative care. These wider indications for use have helped medical professionals to become more tolerant of cannabinoids. Other formulations of the product (such as oils, capsules and transdermal) are being developed, with the goal of improving both patient compliance and ease of use.


Clinical trials and research into new therapeutic areas are also active to increase the use of evidence-based medicine. Regulatory systems are evolving to balance both patient access and patient safety and allow more patients to participate.


Improvements in production technology have increased the quality and yield of cannabis.

Controlled environment agriculture, precision irrigation and other measures have resulted in plants that produce cannabis with higher concentrations and more consistency of cannabinoids. These practices keep up crop quality, lessen resource requirements, and minimize environmental damage.


Further, researchers who cultivate may yield strains for specific therapeutic purposes, improving treatment for individual patients. This regulatory support invests through advanced production facilities and supply chains, strengthening the production infrastructure with patient access.


In the Brazil medical cannabis industry, digitalization makes it easier to engage with and educate patients. Telemedicine, e-prescribing, and patient registries help healthcare professionals treat, monitor compliance, and adjust whenever necessary. This is especially relevant for patients within remote areas without access to cannabis specialists. Mobile apps and websites offer education and symptom monitoring.


Patients have understanding of, also confidence about, the medical use of cannabis-based therapeutics. Patients report relevant outcomes to healthcare providers and researchers within evidence-based medicine. The growing role of digital health with making healthcare more accessible, safer, and tailored to personal patient needs is propelling the market.


Market Segmentation


Species Insights:


  • Indica: One of the main species driving the market, recognized for its therapeutic properties.

  • Sativa: Another key species in the market, valued for its distinctive cannabinoid profile.

  • Hybrid: Combining traits of indica and sativa to meet diverse therapeutic needs.


Derivatives Insights:


  • Cannabidiol (CBD): A prominent derivative used for therapeutic purposes.

  • Tetrahydrocannabinol (THC): A psychoactive component with medicinal applications.

  • Others: Additional derivatives influencing the market dynamics.


Application Insights:


  • Cancer: Medical cannabis is used to manage symptoms and treatment side effects.

  • Arthritis: Cannabis products aid in symptom relief.

  • Migraine: Therapeutic use for managing migraine symptoms.

  • Epilepsy: Utilized to reduce seizure frequencies.

  • Others: Various other medical conditions targeted by cannabis treatments.


Route of Administration Insights:


  • Oral Solutions and Capsules: Popular forms to ensure dosage accuracy and compliance.

  • Vaporizers: Alternative non-invasive delivery systems.

  • Topicals: Used for localized relief through creams and ointments.

  • Others: Additional administration routes expanding patient options.


End Use Insights:


  • Pharmaceutical Industry: Major end users producing medicinal cannabis products.

  • Research and Development Centres: Engaged in clinical trials and product innovation.

  • Others: Additional end-use segments contributing to market demand.


Regional Insights


The report identifies the Southeast region as a key area of focus, alongside South, Northeast, North, and Central-West regions. The market segmentation includes all these regions, acknowledging their relevance in the overall market dynamics. The source does not provide specific quantitative regional market shares or CAGRs beyond this segmentation.


Recent Developments & News


  • In January 2025: MediPharm Labs Corp entered a significant commercial agreement with Laboratório Teuto, a leading pharmaceutical manufacturer in Brazil. This partnership followed ANVISA's granting of sanitary authorizations for two pharmaceutical-grade medical cannabis products made by MediPharm, with approvals published at the end of 2024. The collaboration allows Teuto to leverage its extensive distribution network nationwide, positioning itself as a frontrunner in pharmaceutical cannabis.

  • In January 2024: Avicanna and Ease Labs Pharma secured ANVISA approval to market Brazil’s first THC-containing pharmaceutical preparation. This GMP-certified product comprises 2.5% CBD and up to 0.2% THC, marking a significant milestone for local medical cannabis therapies. The product availability in pharmacies was projected for March 2024.


Key Players


  • MediPharm Labs Corp

  • Laboratório Teuto

  • Avicanna

  • Ease Labs Pharma


Customization Note:


If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.



About Us


IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.


IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.


Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302

 
 
 

Recent Posts

See All

Comments

©2023 by Market Research. All rights reserved.

bottom of page